Shanghai Biostatistics Forum (SBF) 3rd Event, 2012---2012.10.16

http://stat.smmu.edu.cn/upfiles/201210968696.doc

  i, o6 y( ^1 I& MShanghai Biostatistics Forum (SBF) 3rd Event 2012 |Oct 16, 2012 Tuesday, 2pm-5:30pm |Second Military Medical University (SMMU)

' a: o2 C6 ^( m' j( t. u
3 E" o7 ]  O: b5 `) iTheme:
7 `" p; O) H! VPersonalized Medicine in Oncology Clinical Trials
$ q; H# Z! ]1 w4 g  q! wAgenda (2-5:30pm):
3 B1 u0 S# i8 r# r# c$ b* a2 e) {
9 T8 O  g9 e( M§         Opening
Dr. Jacqueline Law (Roche) and Prof. Jia He (SMMU)
( }. o+ R, k+ }/ b2 d+ O( W5 b, p+ \2 N
. Y! L* u+ x1 z% B& U§         OPTIMAL: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer 研究背后故事及结果解读
' z( k! j  u2 y- FSpeaker: Dr.  周彩存 (教授, 主任医师, 上海肺科医院)

5 F6 T" v' f6 X( V% {1 `$ Q: J6 M3 t9 o§         BATTLE: A Clinical Trial Design Applying Bayesian Adaptive Randomization for Targeted Therapy Development in Lung Cancer- A Step Toward Personalized Medicine
5 Q9 \3 F0 I+ b0 Q1 ?. a- Y' USpeaker: Dr. Xian Zhou (Associate Director, Biostatistics, Roche)

§         Development of Herceptin and its diagnostics: a story on the success of personalized medicine
; Z5 U- u- K; b& w' a8 gSpeaker: Dr. Jacqueline Law (AP Biostatistics Site Head, Director, Roche)

2 @' `( r: N+ H' I§         Closing
! ]8 N4 j$ @6 g3 x- U